ARDELYX INC
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
ARDX$3.01+2.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signature Summary of Abbreviated Terms
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Ardelyx, Inc. | ||
| Date: May 1, 2025 | By: | /s/ Joseph Reilly |
|---|---|---|
| Joseph ReillySenior Vice President and Chief Accounting Officer(Principal Accounting Officer) | ||
SUMMARY OF ABBREVIATED TERMS
Throughout this Quarterly Report on Form 10-Q, we have used terms which are defined below:
| 340B Program | Public Health Service’s 340B Drug Pricing Program | GTN | gross-to-net |
|---|---|---|---|
| AAKP | American Association of Kidney Patients | HCR | HealthCare Royalty Partners IV, L.P. |
| ACA | Affordable Care Act | HCR Agreement | Royalty and Sales Milestone Interest Acquisition Agreement |
| AI Technologies | Artificial intelligence, machine learning and certain automated decision-making technologies | HHS | Department of Health and Human Services |
| AMP | average manufacturer price | HIPAA | Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder |
| ANDA | abbreviated New Drug Application | HRSA | Health Resources and Services Administration |
| 2024 Form 10-K | Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 20, 2025 | IBS-C | irritable bowel syndrome with constipation |
| API | active pharmaceutical ingredient | IND | Investigational New Drug |
| AstraZeneca | AstraZeneca AB | IRA | Inflation Reduction Act of 2022 |
| ASU | Accounting Standards Update | IRB | institutional review board |
| CCPA | California Consumer Privacy Act, as amended by the California Privacy Rights Act | Jefferies | Jefferies, LLC |
| cGMP | current Good Manufacturing Practice | Kyowa Kirin | Kyowa Kirin Co., Ltd. |
| CKD | chronic kidney disease | Knight | Knight Therapeutics, Inc. |
| CME | Chicago Mercantile Exchange | MDRP | Medicaid Drug Rebate Program |
| CMO | contract manufacturing organization | METiS | METiS Therapeutics, Inc. |
| CMS | Centers for Medicare & Medicaid Services | MHLW | Ministry of Health, Labour and Welfare |
| CRO | contract research organization | MIPPA | Medicare Improvements for Patients andProviders Act |
| CODM | Chief Operating Decision Maker | OLC | Oxylanthanum Carbonate |
| Customers | collectively, major wholesalers, specialty pharmacies and GPOs (IBSRELA) and specialty wholesaler (XPHOZAH) | NCE | new chemical entity |
| DPF | EU-US Data Privacy Framework | NDA | New Drug Application |
| EEA | European Economic Area | NH3 | sodium hydrogen exchange 3 |
| ESPP | Employee Stock Purchase Plan | NMPA | National Medical Products Administration |
| ESRD | End-Stage Renal Disease | NOL | net operating loss |
| ESRD PPS | End-Stage Renal Disease Prospective Payment System | NMQF | National Minority Quality Forum |
| EU Patent Package | European Patent Package | Non-FAMP | Non-Federal Average Manufacturer Price |
| Exchange Act | the Securities Exchange Act of 1934, as amended | R&D | research and development |
| FASB | Financial Accounting Standards Board | REMS | Risk Evaluation and Mitigation Strategy |
| FDA | Food and Drug Administration | RSU | restricted stock units |
| FFDCA | Federal Food, Drug, and Cosmetic Act | SLR | SLR Investment Corp. |
| Fosun Pharma | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | SEC | Securities and Exchange Commission |
| FSS | Federal Supply Schedule | SOFR | Secured Overnight Financing Rate |
| FTC | Federal Trade Commission | TDAPA | Transitional Drug Add-on Payment Adjustment |
| GAAP | generally accepted accounting principles | UPC | European Unified Patent Court |
| GCP | Good Clinical Practice | U.S. | United States |
| GDPR | European Union General Data Protection Regulation | USPTO | U.S. Patent and Trademark Office |
| GLP | Good Laboratory Practice | VA | Department of Veterans Affairs |
| GPO | group purchasing organization | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.